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Longitudinal Nested Compliance Class Model
in the Presence of Time-Varying
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Julia Y. Lin, Thomas R. TenHave, and Michael R. Elliott

Abstract

This article discusses a nested latent class model for analyzing longitudinal randomized trials when subjects do not always adhere to the treatment to which they
are randomized. In the “Prevention of Suicide in Primary Care Elderly: Collaborative Trial” (PROSPECT) study, subjects were randomized to either the control
treatment, where they received standard care, or to the intervention, where they received standard care in addition to meeting with depression health specialists. The
health specialists educate patients, their families, and physicians about depression
and monitor their treatment. Those randomized to the control treatment have no
access to the health specialists; however, those randomized to the intervention
could choose not to meet with the health specialists, hence, receiving only the
standard care. Subjects participated in the study for two years where depression
severity and adherence to meeting with health specialists were measured at each
follow-up. The outcome of interest is the effect of meeting with the health specialists on depression severity. Traditional ”intention-to-treat” and ”as-treated”
analyses may produce biased causal effect estimates in the presence of subject
noncompliance. Utilizing a nested latent class model that uses subject-specific
and time-invariant ”superclasses” allows us to summarize longitudinal trends of
compliance patterns, and estimate the effect of the intervention using ”intent-totreat” contrasts within principal strata corresponding to longitudinal compliance
behavior patterns. Analyses show that subjects with more severe depression are
more likely to adhere to treatment randomization, and those that are compliant
and meet with health specialists benefit from the meetings and show improvement
in depression. Simulation results show that our estimation procedure produces
reasonable parameter estimates under correct model assumptions.
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Abstract
This article discusses a nested latent class model for analyzing longitudinal randomized trials when subjects do not always adhere to the treatment to which they are randomized.
In the “Prevention of Suicide in Primary Care Elderly: Collaborative Trial” (PROSPECT)
study, subjects were randomized to either the control treatment, where they received standard care, or to the intervention, where they received standard care in addition to meeting
with depression health specialists. The health specialists educate patients, their families,
and physicians about depression and monitor their treatment. Those randomized to the
control treatment have no access to the health specialists; however, those randomized to the
intervention could choose not to meet with the health specialists, hence, receiving only the
standard care. Subjects participated in the study for two years where depression severity
and adherence to meeting with health specialists were measured at each follow-up. The
outcome of interest is the effect of meeting with the health specialists on depression severity. Traditional “intention-to-treat” and “as-treated” analyses may produce biased causal
effect estimates in the presence of subject noncompliance. Utilizing a nested latent class
model that uses subject-specific and time-invariant “superclasses” allows us to summarize
longitudinal trends of compliance patterns, and estimate the effect of the intervention using
“intent-to-treat” contrasts within principal strata corresponding to longitudinal compliance
behavior patterns. Analyses show that subjects with more severe depression are more likely
to adhere to treatment randomization, and those that are compliant and meet with health
specialists benefit from the meetings and show improvement in depression. Simulation results show that our estimation procedure produces reasonable parameter estimates under
correct model assumptions.
KEY WORDS: Longitudinal compliance class model; Principal stratification; Latent class
model; Potential outcomes; Randomized trial; Geriatric depression.

1

INTRODUCTION

We consider longitudinal compliance class models that use hierarchical latent class structures
which characterize subject compliance behavioral patterns over time. More specifically, we
consider studies where subjects are randomized at baseline and the randomization status
remains the same over time, though subject adherence to their randomized treatment may
vary over time. We illustrate the model with analyses of the “Prevention of Suicide in
Primary Care Elderly: Collaborative Trial” (PROSPECT) study (Bruce et al. 2004).
The PROSPECT study was a randomized intervention trial targeted at elderly 64 years of age
or older with clinical depression in primary care clinics. There were two treatment groups:
2
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control treatment, where patients received standard care; and intervention, where patients
met with health specialists in addition to receiving standard care. The health specialists educated patients, families, and physicians about depression and monitored patient adherence
to treatment. Primary care clinics were randomized to the treatment groups rather than
randomization of individual patients for practicality and potential contamination between
patients in the same clinic. Those randomized to the control treatment did not have access
to the health specialists. Patients were randomized to a treatment group only once at baseline, and the randomization status remained constant throughout the study. Patients were
followed up at 4, 8, 12, 18, and 24 months, and at each follow-up their adherence to the
treatment randomization and outcomes were measured. Treatment adherence was measured
by whether patients met with the health specialists at least once since the last follow-up if
randomized to the intervention group. The outcome of the study is the severity of patients’
depression measured by the Hamilton Rating Scale for Depression (HAMD). The HAMD is
a 17-item scale with scores ranging from 0-54. Higher scores indicate more severe depression.
In the PROSPECT study, the baseline HAMD scores ranged from 2-41 with a mean of 18.1
and a standard deviation of 6.0. Patient suicidal ideation was measured at baseline and 26%
of our study sample had suicidal ideation. We are interested in the effect of the intervention
on depression controlling for treatment non-adherence.
Estimating the causal effects of experimental manipulations becomes complicated in the
presence of subject noncompliance (Little and Rubin 2000). Traditionally, the intentionto-treat (ITT) and as-treated (AT) analyses are performed but these two methods do not
always allow us to obtain unbiased estimates of the causal effects of the treatment on outcomes in the presence of treatment noncompliance. The relationship between experimental
manipulation and the outcome may be confounded by treatment non-adherence. Hence, it
may be important to account for compliance behavior in the presence of subject noncompliance when estimating treatment effects. Compliers and noncompliers may be inherently
different, which could affect how they respond to treatment randomization, as well as the
actual treatment itself (Heitjan 1999; Frangakis and Rubin 1999; Mealli, Imbens, Ferro, and
Biggeri 2004).
3
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Baker and Lindeman (1994), Angrist, Imbens, and Rubin (1996), and Imbens and Rubin (1997) suggested using latent compliance classes to characterize compliance behavior,
within which the effect of treatments are estimated to account for compliance behavior. In a
cross-sectional two-arm randomized experimental study, where treatment-received is binary
(experimental or control treatment), and subjects have access to the experimental or control
treatment regardless of treatment randomization, there are four possible compliance classes:
compliers, those that would adhere to the treatment to which they are randomized; alwaystakers, those that would always seek the experimental treatment regardless of the treatment
to which they are randomized; never-takers, those that would always opt for the control
treatment regardless of the treatment to which they are randomized; and defiers, those that
would seek the treatment opposite to the arm to which they are randomized. Estimating the
effect of the experimental treatment while controlling for compliance behavior can be accomplished by estimating the ITT effects within compliance classes via comparing the potential
outcomes under each randomization arm stratified on compliance classes. The Imbens and
Rubin (1997) approach allows us to examine the effect of the experimental treatment in
particular population of interest such as the compliers (i.e. complier average causal effect;
CACE), for which the ITT contrast is a valid estimate of the direct effect of treatment on
the outcome under certain assumptions (Angrist et al. 1996; Little and Rubin 2000).
Compliance classes are latent variables related to randomization status and actual treatment
received. They fall under the principal stratification framework, and can be thought of as
“compliance principal strata,” such as in Imbens and Rubin (1997), and Frangakis and
Rubin (1999, 2002), where principal strata were defined by compliance classes. Knowing
the randomization status and the actual treatment received does not completely determine
the compliance class. For example, an individual randomized to the control treatment and
receives the control treatment could be a complier or a never-taker but not an always-taker
or a defier. The probabilities of subject compliance class membership can be estimated in a
Bayesian framework (Imbens and Rubin 1997; Frangakis and Rubin 1999; Hirano, Imbens,
Rubin, and Zhou 2000), or in a frequentist framework (Little and Yau 1998; Jo and Muthén
2001). Peng, Little, and Raghunathan (2004) compared Bayesian methods to frequentist
4
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methods and concluded that both methods yield similar results.
Not all two-arm cross-sectional studies provide four possible compliance classes. For example,
in the PROSPECT study where subjects randomized to the control treatment have no access
to the experimental treatment, there are only two possible compliance classes: compliers and
never-takers. Since no subjects randomized to the control treatment could be observed to
receive the experimental treatment, there are no always-takers and defiers. In this setting,
compliance classes are partially latent. Subjects assigned to the treatment arm are either
observed to be compliers if they receive the experimental treatment, or never-takers if they do
not receive the experimental treatment. However, these compliance classes are not observed
for those randomized to the control arm.
We extend the Imbens and Rubin (1997) method to longitudinal settings where treatment is
randomized once initially but treatment is applied multiple times throughout the study, and
outcomes are repeatedly measured over time. Subject compliance behavior is allowed to vary
over time (i.e. treatment received could be different at each follow-up period). We model
the relationship between latent, or partially observed, longitudinal compliance patterns and
longitudinal outcomes.
There have been other extensions of the Imbens and Rubin’s (1997) method to longitudinal
settings. Yau and Little (2001) extended Imbens and Rubin’s (1997) method to a study
where treatment was randomized initially and treatment was applied only once, and outcomes were measured repeatedly over time. Treatment compliance was measured by initial
treatment randomization and actual treatment received, and did not vary over time. Frangakis et al. (2004) extended the model to a study where randomization and treatment were
administered at multiple times throughout the study, and longitudinal outcomes were measured. Treatment compliance was measured repeatedly over time, and was allowed to vary
over time.
The proposed method differs from the method in Yau and Little (2001) in that we allow timevarying treatment compliance. It also differs from the method in Frangakis et al. (2004)

5
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in two ways: 1) we assume that randomization is constant across time; 2) we incorporate a
hierarchical latent class structure that consists of time-varying compliance nested in classes
of longitudinal compliance trends that are time-invariant. Our method provides summary
measures of longitudinal compliance behaviors, and estimates ITT effects within overall
compliance behavioral trends.
In longitudinal studies where randomization status remains constant but treatment compliance can vary over time, ITT contrasts must be made with respect to the longitudinal
compliance class patterns, which can be thought of as pre-existing, though unobserved,
subject-level characteristics at the time of randomization. Thus one might consider the
set of potential outcomes for a given compliance pattern, for example, any subject who
would have been a complier at every time point. However, it may be useful to characterize longitudinal compliance patterns and estimate the causal effect of treatment conditional
on general longitudinal compliance profiles, which we denote as “superclasses”. We propose to use latent class models to create subject-specific and time-invariant “superclasses”
to describe longitudinal trends of compliance patterns. This allows us to obtain a baseline,
time-invariant compliance class structure based on time-varying compliance information that
we can utilize in a potential outcomes framework. These “superclasses” become the principal strata (Frangakis and Rubin 2002; Frangakis et al. 2004) within which we estimate
the effect of randomization over time. Thus, if the data suggests there are, e.g. “highly
compliant,” “highly noncompliant,” and “early compliant” superclasses, we could consider
the effect of randomization among the “highly compliant” as a measure of clinical interest.
The time-varying compliance classes in the PROSPECT study are functions of subjects’
initial treatment randomization and their actual treatments received at each follow-up, and
the superclasses are functions of subjects’ compliance classes over time.
We will define notation, discuss assumptions, principal effect of interest, parametric models,
parameter estimation, and assessment of model fit in Section 2, and discuss analysis and
simulation results in Section 3, then proceed to discussion and future work in Section 4.

6
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2

2.1

LONGITUDINAL PRINCIPAL STRATIFICATION
MODEL
Notation

Let Zi denote randomization for subject i where i = (1, ..., N ) and Zi ∈ (0, 1) for standard
care and the intervention, respectively. Similarly, let Dij denote treatment received for
subject i at time j where j = (1, 2, 3, 4, 5) for 4, 8, 12, 18, and 24 months, respectively, and
Dij ∈ (0, 1) for standard care and the intervention, respectively. Note that Zi does not have
index j because we are restricting to designs in which randomization remains constant over
time. Let Yij denote the observed HAMD score for subject i at time j. We use Z, D, and
Y to denote the vector of Zi , Dij , and Yij . Not all subjects have data for all 5 follow-ups,
so let Ji denote the last follow-up visit of subject i where Ji ∈ (1, 2, 3, 4, 5).
Extending the notation of Angrist et al. (1996), we identify two types of potential outcomes:
Dij (Z) and Yij (Z, D(Z)). Let Dij (Z) denote the potential treatment received at time j if
subject i is randomized to treatment Z; and let Yij (Z, D(Z)) denote the potential outcome
for subject i at time j if randomized to group Z and received treatment D(Z). In this paper,
we use upper case letters to denote random variables or indices for potential outcomes (e.g.
Dij (Z)), and lower case letters for realized or observed values of these random variables or
potential indices (e.g. Zi = z).
In PROSPECT, patients who are randomized to the control treatment do not have access
to the health specialists; therefore, there are only two possible compliance classes: compliers
and never-takers. Let Cij denote the latent compliance class for subject i at time j where
Cij ∈ (c, n) for compliers and never-takers, respectively. We use C to denote the vector of
Cij . The potential treatment received, Dij (0) and Dij (1), define compliance class: Cij = c
if Dij (0) = 0 and Dij (1) = 1, and Cij = n if Dij (0) = 0 and Dij (1) = 0. In studies where
those randomized to the control treatment have no access to the intervention, the compliance
classes are observed among those randomized to the intervention group: Cij = c if Zi = 1
and Dij = 1 and Cij = n if Zi = 1 and Dij = 0.
7
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Note that Dij (Z) is a deterministic function of Cij . If we know the compliance class of an
individual, then we know the potential treatment received of that individual. Therefore,
the notation (Yij (Z)|Cij ) is equivalent to Yij (Z, D(Z)) where Yij (Z) denotes the potential
outcome for subject i at time j if randomized to group Z.
In studies such as the PROSPECT where subjects are followed longitudinally and subject
compliance behavior could vary over time, the number of possible compliance patterns increases exponentially with time. With two possible compliance classes (i.e. compliers and
never-takers) and five time points, we have 25 = 32 possible compliance patterns. We propose to use compliance “superclasses” to summarize compliance patterns present in the data,
in which we can stratify on to compare potential outcomes. Let Ui denote the compliance
superclass for subject i where Ui ∈ (1, ..., K), and we use U to denote the vector of Ui .
Subject-level baseline covariates Ai and Qi are used in modelling the outcome and the
probability of compliance class membership, respectively. We use A and Q to denote vectors
of Ai and Qi . These models are discussed in more detail in Section 2.4.

2.2

Assumptions

The randomization assumption and the stable unit-treatment value assumption (SUTVA)
are made to identify the potential outcomes and the effect of the treatment using observed
outcomes.
The randomization assumption implies that conditional on observed baseline covariates (e.g.
baseline HAMD score and suicide ideation), treatment randomization is independent of all
baseline variables or pre-randomization variables (e.g. latent baseline characteristics) and
potential outcomes (Rubin 1978).
We implicitly make the stable unit-treatment value assumption (SUTVA) of no interference
between units when we write Dij (Z) and Yij (Z, D(Z)) instead of Dij (Z) and Yij (Z, D(Z)),
where D(Z) is a vector of potential treatment received for all participants. The SUTVA no

8
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interference assumption says that the compliance behavior of one individual is not affected
by randomization status of other individuals, and the potential outcome of one individual
is not affected by the randomization and compliance behaviors of other individuals. Note
that we are only assuming independence between subjects and do not assume independence
within subjects.
Identification of potential outcomes also require SUTVA’s consistency assumption (Rubin
1986). It assumes that the potential outcome of a certain treatment will be the same regardless of the treatment assignment mechanism. This assumption may be violated when there
are version of a treatment not reflected in the treatment indicator variable. The consistency
assumption implies that the potential outcome Yij (Z = z, D(Z = z)) for observed z is the
observed outcome conditional on Zi = z, and the potential treatment received Dij (Z = z) for
observed z is the observed treatment received conditional on Zi = z. Under this assumption,
the observed outcome is a function of the potential outcomes and the observed randomization status, and the observed treatment received is a function of the potential treatment
received and observed randomization status: Yij = Zi ∗ Yij (1, D(1)) + (1 − Zi ) ∗ Yij (0, D(0))
and Dij = Zi ∗ Dij (1) + (1 − Zi ) ∗ Dij (0).

2.3

Principal Effects

If we attempt to estimate ITT effect within each of the 32 possible combinations of the
time-varying compliance classes in the PROSPECT study, we may encounter the problem
of having little or no subjects in some of the patterns, and inference based on such estimates
would be highly sensitive to modelling assumptions. We would also have 32 ITT effects for
the different compliance patterns, which could make interpretation of the results difficult,
and may be of limited use clinically.
An alternative to stratifying on the time-varying compliance classes is to stratify on “compliance superclasses” that characterize longitudinal compliance patterns. The superclasses
serve as summary measures of compliance patterns within which we estimate ITT effects of

9
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the experimental treatment. A compliance superclass is a pre-randomization variable, which
allows us to model potential outcomes, just as we do with compliance classes. It is a latent
variable at the subject level; unlike the time-varying compliance classes as we defined here,
which is at both subject and time level. The effect of interest would be the principal effect
of treatment assignment on the outcome at time j within a compliance superclass:
E[Yij (Z = 1)|Ui = k] − E[Yij (Z = 0)|Ui = k]
This principal effect is a standard ITT contrast, although stratified on the latent compliance
superclass, which allows us to consider the effect of randomization on the outcome controlling
for subject longitudinal compliance behavior. Since the compliance superclasses do not
represent exact longitudinal compliance class patterns, this principal effect does not translate
to the CACE in Angrist et al. (1996). We discuss details of the superclass model in Section
2.4.
The principal effect of interest can be identified through the observed data by making the
randomization and the SUTVA consistency assumptions:

E[Yij (Z = 1)|Ui = k] − E[Yij (Z = 0)|Ui = k]
= E[Yij (Z = 1)|Zi = 1, Ui = k] − E[Yij (Z = 0)|Zi = 0, Ui = k]
= E[Yij |Zi = 1, Ui = k] − E[Yij |Zi = 0, Ui = k].

The first equality follows from the randomization assumption which assumes independence
between baseline characteristics, such as potential outcomes, and the randomization status
conditional on other baseline factors, such as Ui . The second equality follow from SUTVA’s
consistency assumption, which assumes that the observed outcomes are functions of the
potential outcomes and the observed randomization status. Assuming the randomization and
the SUTVA consistency assumptions, we can utilize observed outcomes to model potential
outcomes.

10
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2.4

Parametric Models

Consider the complete data that consist of randomization status, potential outcomes, and
potential treatment received. Let f (.) denote the distribution function. The complete data
distribution is given by:

f (Z1 , · · · , ZN , Y11 (Z = 0), · · · , YN JN (Z = 0), Y11 (Z = 1), · · · , YN JN (Z = 1),
Di1 (Z = 0), · · · , DN JN (Z = 0), Di1 (Z = 1), · · · , DN JN (Z = 1))
N
Y
=
f (Zi = z)f (Yi1 (Z = 0), · · · , YiJi (Z = 1), Di1 (Z = 0), · · · , DiJi (Z = 1))

(1)

i=1

The equality follows from the randomization and the SUTVA no interference assumptions.
The distribution of the observed data (Yi1 , · · · , YiJi ,Di1 , · · · , DiJi ) for subject i is given by:
f (Yi1 , · · · , YiJi , Di1 , · · · , DiJi |θ)
Z Z
=
f (Yi1 (Z = 0), · · · , YiJi (Z = 1), Di1 (Z = 0), · · · , DiJi (Z = 1)|θ) dYimis dDimis
Z Z
=
f (Yi1 (Z = 0), · · · , YiJi (Z = 1)|Di1 (Z = 0), · · · , DiJi (Z = 1), θ)
Z Z

f (Yi1 (Z = 0), · · · , YiJi (Z = 1)|Ci1 , · · · , CiJi , Ui , θY )

=
Z Z
=

f (Di1 (Z = 0), · · · , DiJi (Z = 1)|θ) dYimis dDimis
(2)

f (Ci1 , · · · , CiJi |Ui , θC )f (Ui |θU ) dYimis dDimis
f (Yi1 (Z = 0), · · · , YiJi (Z = 1)|Ci1 , · · · , CiJi , θY )
f (Ci1 , · · · , CiJi |Ui , θC )f (Ui |θU ) dYimis dDimis

where Yimis and Dimis contains the Yij (Z) and Dij (Z) for which Z 6= Zi , and θ = (θY , θC , θU )
where θY parameterizes the distribution of the potential outcomes Yij (Z), and θC and θU
parameterize the latent compliance class and superclass model for Cij and Ui .
Following Hirano et al. (2000) and Imbens and Rubin (1997), we model the outcome conditional on partially latent compliance class, randomization, and covariates. We consider a
hierarchical model structure, similar to Elliott, Gallo, Ten Have, Bogner, and Katz (2005)
11
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and Hogan and Daniels (2002), to account for subject-level random effect. Outcomes are
assumed to be conditionally independent given compliance classes Ci1 , · · · , Cij , treatment
assignment Zi , subject-level baseline covariates Ai , and subject-level random effect ϕi :
¡
¢
2
Yij |Ci1 , · · · , Cij , Zi = z, Ai , Wi , λ, ζ(t, j), γ, ϕi , σ 2 ind
∼ N (µijz , σ )
"
#
j
X
X
µijz =
I(Cit = η 0 , Zi = z)λtη0 z ζ(t, j) + ATi γ + WiT ϕi
t=1

(3)

η0

Let λ denotes the vector of λtη0 z . The within-compliance class effect of randomization on
i
Pj hP
0
the outcome is represented by t=1
η 0 I(Cit = η , Zi = z)λtη 0 z ζ(t, j) , where I(H) is an
indicator function that equals to 1 if H is true, and 0 otherwise. We use ζ(t, j) to describe
the relationship between compliance class membership at time t on the outcome at time j,
where t ≤ j. If we assume a transient relationship, where outcome is assumed to depend
only on the compliance behavior in the current time period, then ζ(t, j) = I(t = j); if we
assume a non-transient relationship, where outcome is assumed to dependent on compliance
behavior in the current and all prior time periods, then ζ(t, j) = I(t ≤ j); if we assume a
decaying relationship, where outcome is assumed to be dependent on compliance behavior in
the current and all prior time periods, but the effect diminishes as time lag increases, then
we may assume ζ(t, j) = e−τ (j−t) where τ > 0.
The fixed effect of subject-level baseline covariates Ai on the outcome are described by the
column vector γ. The random effect ϕi is used to account for the within-subject correlation in
the outcomes where Wi denotes the random effect design matrix of subject i. A preliminary
analysis indicated that the within-clinic correlation was small (0.075); hence we ignore it for
this analysis. Subject-level random effects are assumed to be independent of random errors
of the outcome, and of the latent classes Cij and Ui for all i and j.
We assume that the compliance superclass is an underlying factor that drives subject compliance over time; therefore, we model the time-varying compliance class conditional on compliance superclass. Following Hirano et al. (2000) and Ten Have, Elliott, Joffe, Zanutto, and
Datto (2004), we model the compliance class probabilities conditional on baseline covariates
12
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P
Qi . Let P (Cij = η|Ui = k, Qi ) = πkjη (Qi ), and πkjη (Qi ) = exp(α0kjη +α1η Qi )/[ η0 exp(α0kjη0 +
P
α1η0 Qi )] ,where η0 πkjη0 (Qi ) = 1 ∀k, j (Clogg 1995), and we constrain α0kjη∗ and α1η∗ for
one of the compliance class η ∗ to be 0 for identifiability. This multinomial logit model assumes a constant effect of the baseline covariates Qi on the compliance class probabilities
that does not vary by time nor compliance superclass. Compliance classes between subjects and compliance classes within a subject at each time point conditional on compliance
superclass and baseline covariates are assume to be independent:
P (C|U, Q) =

N
Y

P (Ci1 , ..., CiJi |Ui , Qi ) =

i=1

N
Y

P (Ci1 |Ui , Qi )...P (CiJi |Ui , Qi ).

i=1

Assuming conditional independence between compliance classes given superclass, estimates
of the λ parameters do not change with different ζ(t, j). We prove this in the Appendix.
This allows us to use the transient conditional mean outcome model in analysis, where
ζ(t, j) = I(t = j), regardless of the true relationship between the compliance classes and the
outcomes. Thus, equation (3) becomes µijz = I(Cij = η, Zi = z)λjηz + ATi γ + WiT ϕi .
We assume that subject compliance superclass (Ui = k) ∼ M ultinomial(1, pk ), where
PK
k=1 pk = 1. Compliance superclasses between subjects are assumed to be independent:
Q
f (U) = N
i=1 f (Ui = k) for k = 1, ..., K. We assume that there are no covariates associated
with compliance besides the covariates Qi used in modelling time-varying compliance, and
therefore, do not include any covariates in modelling the superclasses. Covariates can be
incorporated using multinomial logit models.

13
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Given the model specifications, Equation (2) becomes
Z Z
f (Yi1 (Z = 0), · · · , YiJi (Z = 1)|Ci1 , · · · , CiJi , θY )
f (Ci1 , · · · , CiJi |Ui , θC )f (Ui |θU ) dYimis dDimis
Z Z
=
f (Yi1 (Z = 0), Yi1 (Z = 1)|Ci1 , θY ) · · · f (YiJi (Z = 0), YiJi (Z = 1)|CiJi , θY )
f (Ci1 |Ui , θC ) · · · f (CiJi |Ui , θC )f (Ui |θU ) dYimis dDimis

³

´ I(Zi =0)
Y −(λ +AT γ +WiT ϕi )
Ji X
K
Y
πk0 jc (Qi ) × φ ij jc0 σi
+
³
´ 
= 
pk 0 
×
T
T
Y −(λ
+A γ +Wi ϕi )
πk0 jn (Qi ) × φ ij jn0 σi
j=1 k0 =1
I(Zi =1)

¶
µ
K
T
T
Y X
Yij − (λjc1 + Ai γ + Wi ϕi ) 

×
pk0 φ
σ
0
j∈Dij =1 k =1


µ
¶ I(Zi =1)
K
T
T
Y X
Yij − (λjn1 + Ai γ + Wi ϕi ) 

pk0 φ
σ
j∈D =0 k0 =1
ij

where φ(s) is the pdf for standard normal distribution evaluated at s.

2.5

Estimation

We use the Bayesian Markov Chain Monte Carlo (MCMC) method to estimate model parameters. The model set up is similar to the methods used in Hirano et al. (2000) and Ten
Have et al. (2004). Bayesian estimation of latent compliance classes proposed by Imbens and
Rubin (1997) requires specifying prior distribution. We assume α ∼ M V N (0, Σα ) (Garrett
and Zeger 2000; Ten Have et al. 2004), and the prior (p1 , ..., pK ) ∼ Dirichlet(a1 , ..., aK ).
For notational simplicity, let Xij = [I(Ci1 = c, Zi = 0), · · · , I(Ci5 = n, Zi = 1), Ai ] denote
the row vector of the fixed effect, and Xi denotes the design matrix of the fixed effect for
subject i with Ji rows. Let β = [λ1c0 , · · · , λ5n1 , γ] denote the vector of coefficients corresponding to the fixed effect. We put a priors on the vector of fixed effect parameters
β ∼ M V N (µβ , Σβ ), the random effect parameters, ϕi ∼ M V N (0, Σϕ ), and conjugate
hyperprior, Σϕ ∼ Inv − W ishart (df = νϕ , Γ). We also assume a conjugate prior for the
variance of the random errors, σ 2 ∼ Inv − χ2 (df = νσ , ψ). Gibbs sampling (Geman and
14
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Geman 1984; Gelfand and Smith 1990; Imbens and Rubin 1997; Gelman, Carlin, Stern, and
Rubin 2004) is used to obtain draws from the posterior distributions of the parameters. The
detailed description of the posterior distributions of β, σ 2 , ϕi , Σϕ , Cij , pk , and Ui from which
the parameters are drawn are given in the Appendix.
Since the posterior distributions of (α|C, U, Q) is not of a known parametric form, we propose to use the Metropolis-Hasting algorithm (Hastings 1970; Gelman et al. 2004) technique
to draw the α parameters. We use the multivariate t-distribution with 3 degrees of freedom
as the proposal distribution, using estimates of α from the previous iteration and the inverse
of the observed information as the mean and variance, respectively.

2.6

Model Fit Assessment

To assess the fit of the model to the data we examine the posterior predictive distributions
(PPD; Gelman et al. 2004). Since the compliance classes in those randomized to the intervention are observed, we compare the PPD of the time-varying compliance classes in those
randomized to the intervention and assess their fit to the observed compliance. Let Gm denote the number of individuals in mth of the 32 possible longitudinal compliance patterns and
let κm be the estimated probability of exhibiting the mth longitudinal compliance pattern.
We consider the χ2 -type statistics:
S obs =

X (Gobs − N κm )2
m

m

N κm (1 − κm )

and S rep =

X (Grep − N κm )2
m

m

(4)

N κm (1 − κm )

rep
where Gobs
m is the observed statistics and Gm is the repeated statistic obtained from draws

of the parameters generated by the Gibbs sampler. The PPD p-value is then given by
P
obs l
) < (S rep )l ]
l I[(S P
l1
where (S obs )l and (S rep )l denote the S obs and S rep from lth Gibbs draw, respectively. A PPD
p-value close to 0.50 indicates good fit of the model to the data.
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3

RESULTS

In the PROSPECT study, 320 subjects were in clinics that were randomized to intervention,
and 278 were in clinics that were randomized to the standard care. All subjects at each time
point that have not dropped out of the study and have HAMD measures are considered for
the analysis. At the 4-month follow-up, 234 remained of those randomized to standard care
and had HAMD measures, and 253 remained of those randomized to the intervention and
had HAMD measures. Of those 253 who were randomized to the intervention, 30 received
the standard care instead, and no one randomized to the standard care was observed to
have received the intervention as the intervention would not have been accessible to them.
At the 24-month follow-up, 151 were left of those randomized to the standard care and had
HAMD measures, and 170 remained of those randomized to the intervention and had HAMD
measures. Of those 170, 48 received the standard care instead. We assume that dropouts and
missing outcomes are occurring at random (MAR; Little and Rubin 2002). We include the
baseline HAMD score and baseline suicidal ideation in modelling the outcome because we are
interested in the change in HAMD from baseline in each subject and because randomization
failed to balance proportions of subjects with suicidal ideation between the control and the
intervention groups at baseline (Bruce et al. 2004). ITT analysis and AT analysis will be
performed in addition to analysis based on the superclass model for comparison.

3.1

ITT analysis

In an ITT analysis, we ignore the treatment that subjects actually received, and look at the
effect of randomization on the outcome. In this analysis, we fit a linear mixed effects model
with random subject-level intercepts, and we control for baseline HAMD score and baseline
suicidal ideation. Table 1 shows that the effect of being randomized to meet with health
specialists is strongest during the first four months of the study with an average of a 3-point
reduction in the HAMD score. The effect diminishes until the 24-month follow-up where
we see an increase in reduction of HAMD score in those that were randomized to meet the

16

http://biostats.bepress.com/upennbiostat/art10

health specialists relative to those that were randomized to the usual care.
An ITT effect can provide biased estimates of the direct effect of the intervention when
subject noncompliance is present and not accounted for in the analysis. It may not reflects
the effect of the intervention because the subjects’ randomization status is not necessarily
the same as the actual treatment received.

3.2

AT analysis

In an AT analysis, we ignore the subject randomization status, and look at the effect of
the actual intervention received on the outcome. In this AT analysis, we also fit a linear
mixed effects model controlling for baseline HAMD score and baseline suicidal ideation,
with subject-level random intercepts. The AT analysis result is shown in Table 1. The effect
of actually meeting the health specialists is the strongest during the first four months of
the study. The effect diminishes until the 24-month follow-up where we see an increase in
reduction of HAMD scores in those who met with the health specialists relative to those who
did not. In contrast to the ITT effect, the AT effect is significant over the entire observation
period.
AT estimates of the effect of the intervention may also be biased in the presence of noncompliance or confounders related to the treatments and the outcome (Heitjan 1999). When we
ignore the randomization, the groups may no longer be comparable.

3.3

Superclass Model

In this section we consider the application of our extension of the Imbens and Rubin (1997)
method to a longitudinal case where randomization stays constant over time but the treatment received could vary. We consider a transient model, where outcomes are only dependent
on current compliance behavior and not prior compliance behavior. Under the conditional
independence assumption for the compliance classes given compliance superclass, estimates
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obtained under the transient model are equal to those obtained under a non-transient model
as shown in the Appendix. The effect of interest is the principal effect of treatment assignment on the outcome within a compliance superclass controlling for baseline HAMD score
and baseline suicidal ideation:

E[Yij (Zi = 1)|Ui = k] − E[Yij (Zi = 0)|Ui = k] =

X

πkjη0 (Qi ) × (λjη0 1 − λjη0 0 )

(5)

η0

In PROSPECT, those randomized to the usual care have no access to the health specialists;
hence, there are only two possible compliance classes: complier and never-taker. We include
baseline HAMD score in modelling the compliance probabilities.
In our superclass model we use priors that are not informative for the Bayesian MCMC
algorithm because we do not have strong a priori inclinations. We assume
α ∼ M V N (0, Σα = diag(9/4, 0.04)) for intercepts and coefficient for the effect of baseline
HAMD score on compliance class probabilities following Garrett and Zeger (2000) and Ten
Have et al. (2004). The difference in the variance component in the prior reflects the different scaling of the covariates. A larger variance is used for binary covariates (intercept) and
a smaller variance is used for continuous covariates (baseline HAMD score). We assume a
noninformative prior (p1 , ..., pK ) ∼ Dirichlet(1, ..., 1) for the compliance superclass probabilities. We assume a diffuse prior on the coefficients for the within-compliance class effect
of randomization, baseline HAMD score, and baseline suicidal ideation on the outcomes,
β ∼ M V N (µβ = 0, Σβ = 1000 × I). In this analysis, we assume a model with subject-level
intercepts and assume the conjugate prior Σϕ ∼ Inv−χ2 (νϕ = 1, Γ = 1/10). We also assume
a conjugate prior for the variance of the random errors, σ 2 ∼ Inv − χ2 (νσ = 1, ψ = 1/10).
Identifiability of the α parameters is checked by comparing the prior and posterior distributions (Garrett and Zeger 2000).
We assume there are three compliance superclasses. Goodman (1974) suggests that we can
only identify at most 3 latent compliance superclasses given we have dichotomous compliance
classes for 5 time points.
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We run 3 MCMC chains of 5,000 iterations after discarding 5,000 iterations of burn-in. To
deal with possible label switching of the latent classes from one iteration to another, we use
the algorithm proposed by Stephens (2000) to ensure that the labels of latent classes in one
iteration is equivalent to the labels in other iterations. To assess the convergence of the
chains, we calculate the R̂ statistic (Gelman et al. 2004, pp.296-297) which is the square
root of the ratio between the weighted average of the within- and between-chain variance
and the within-chain variance. R̂ = 1 is considered convergence, and R̂ < 1.1 is acceptable;
our maximum value of R̂ was 1.04.
Table 2 shows the compliance probabilities at each follow-up within each compliance superclasses given an average HAMD of 18.1. We see that the probability of membership in the
complier class is low in the first superclass, and it decrease over the first year then stabilizes
in the second year. We will call this superclass “low compliers”. In the second superclass, the
probability of compliance starts high then rapidly decreases over time. We will call this superclass “decreasing compliers.” In the third superclass, the probability of compliance is near
1, and remains high for the first 18 months, then drops off slightly in the last 6 months. We
will call this last superclass “high compliers.” The posterior probabilities and their associated
95% credible interval of membership in the low compliers, decreasing compliers, and high
compliers superclasses are 0.19(0.12,0.26), 0.07(0.00,0.14), and 0.74(0.67,0.80), respectively.
The posterior mean and 95% credible interval for the log odds of complier class membership with an one-point increase in baseline HAMD score is 0.04(-0.004,0.08). It suggests
that patients with more severe depression at baseline, indicated by higher baseline HAMD
scores, are more likely to be compliers than never-takers compared to those with less severe
depression at baseline.
Table 3 presents the posterior means and credible intervals of (5), the ITT effect of randomization on the outcome within each compliance superclass controlling for baseline HAMD
and baseline suicidal ideation. The ITT contrast within the low compliers shows a large
decrease in the HAMD score at 4 months, suggesting that those in clinics randomized to
the intervention show greater improvement in depression than those in clinics randomized to
19

Hosted by The Berkeley Electronic Press

the usual care. Never-takers receive the usual care regardless of their randomization status;
therefore, the ITT effect at 4 months in the low complier superclass is likely to be largely
contributed by the direct effect of randomization. We also see a reduction in HAMD scores
in the ITT contrasts within decreasing compliers and high compliers, who are highly compliant at 4 month, suggesting that meeting the health specialists when randomized to the
intervention may be effective in improving the status of depression. At 24 months, we see
the largest reduction in HAMD in the ITT contrast of the high complier superclass. These
findings suggest that although being in clinics randomized to the intervention, or having access to the health specialists, may help improve depression initially, subjects need to actually
meet with the health specialists to benefit from the intervention longitudinally.
We compare the fit of the posterior predictive distribution (PPD) of the longitudinal compliance class patterns in those randomized to the intervention under the two-superclass model
to that under the three-superclass model. The PPD p-value for the two-superclass model
is 0.003, and is 0.046 for the three-superclass model. This gives evidence that the threesuperclass model has a better fit to the data than the two-superclass model.

3.4

Simulation Study

We simulated 100 data sets of 400 subjects each with complete 5 follow-up visits assuming there are two superclasses: increasing-noncompliers, whose compliance probabilities are
0.50, 0.40, 0.30, 0.20, and 0.10 from the first visit to the fifth visit; steady-compliers, whose
compliance probabilities are 0.90 throughout all the visits. We assume equal probabilities of
being increasing-noncompliers and steady-compliers. We also assume the variances σ 2 = 22
and Σϕ = 25. We simulated the data under β = (5.84, 2.79, 5.23, 2.38, 3.65, 2.12, 3.51,
1.65, 2.46, 1.49, 3.56, 2.21, 1.96, 1.16, 2.73, 3.51, 1.70, −0.04, 2.38, 2.43, 0.44) which corresponds
to ITT effects in the increasing-noncompliers as -2.950, -1.728, -1.236, 0.464, and -0.129 from
the fist visit to the last visit, and ITT effects in the steady-compliers as -3.030, -1.563, -1.008,
-0.642, and -1.561. We analyze the simulated data assuming the correct model structure.
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The means of the estimated compliance probabilities, the compliance superclass probabilities,
and the ITT effect within each superclass of the simulated data sets are presented in Table 4.
Our estimation procedure seems to perform well in estimating the compliance probabilities
and the compliance superclass probabilities. The estimated values are very close to the true
values from which the data is simulated. The estimated ITT effects within superclasses also
seem reasonable relative to the true values. Table 5 presents the coverage of the 95% credible
intervals of the estimates. It shows good coverage for the compliance probability and ITT
effect estimates. We see an over-coverage of the compliance superclass probability estimates.
A binary variable is expected to have the largest variance when the probability of “success”
is at 0.5. Therefore, we expect the variance of the compliance superclass probabilities to be
the largest when the true probability of being in one of two classes is 0.5.

4

DISCUSSION

The proposed model extends the methods in Imbens and Rubin (1997) and Yau and Little
(2001) to longitudinal data where randomization is constant through time but the compliance behavior may vary over time. Similar to Frangakis et al. (2004), the proposed model
accommodates time-varying latent classes. However, unlike Frangakis et al. (2004), we do
not allow randomization to vary over time. Another difference between the proposed model
and the model in Frangakis et al. (2004) is that we utilize a nested latent class structure
to summarize longitudinal time-varying compliance behaviors and estimate principal effects
within the time-invariant subject-specific compliance superclasses. The proposed method
allows us to make ITT contrasts controlling for longitudinal compliance behaviors by stratifying on the compliance superclasses. If we were to compare outcomes stratified on specific
patterns of compliance over time, it may result in too many comparisons to be of any practical use, or we may run into problems with small sample sizes in some of the patterns.
Furthermore, the Imbens and Rubin (1997) framework allows us to assess the direct effect
of randomization on the outcome. Although utilizing the superclasses provide convenient
summaries of the longitudinal compliance patterns, we lose the ability to have clear causal
21
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interpretations of the stratified ITT contrasts.
In the PROSPECT study, we found a relationship between baseline depression severity and
compliance behaviors. Those with more severe depression at baseline, indicated by higher
HAMD score, are more likely to be compliers than never-takers than those with less severe
depression. It is sensible that those with more severe depression would be more cooperative
in working with their physicians to improve their condition, and be more willing to adhere
to the treatment to which they are randomized. Those with less severe depression may not
feel the need for treatment; hence, reject intervention when it is available to them.
We identified three types of longitudinal compliance profiles in the analysis: 1) low compliance; 2) decreasing compliance and 3) high compliance. The ITT contrasts at each time
point within superclasses suggest that there may be a direct effect of randomization initially,
but those who are more compliant and met with health specialists when randomized to the
intervention showed greater improvement in depression than those who are less compliant
at the end of the study. This suggests that meeting with health specialists is effective in
improving depression. Although those who did not comply when randomized to the intervention still showed reduction in the HAMD score early in the study, those who complied
were able to benefit from meeting with the health specialists and showed greater reduction
in the HAMD score longitudinally. An advantage of our approach over a cross-sectional ITT
analysis, and over even a cross-sectional principal stratum analysis, is that we were able to
identify a latent class of highly compliant individuals whose ITT effects at later time periods were greater than those estimated through conventional approaches, consistent with a
hypothesis of treatment benefit.
The proposed nested latent class model also allows us to examine the direct effect of randomization. In groups with large proportion of never-takers, such as in our low complier
superclass, the ITT effects are likely due to the direct effect of randomization rather than the
effect of the actual intervention. In the PROSPECT study, we found evidence of direct effect
of randomization early on but the effect diminished over time. In large clinical randomization studies, clustered randomization are often performed due to concerns of contamination
22
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between subjects in the same cluster randomized to different treatment groups. Our result
suggests that with adequate run-in time for the intervention, the effect of randomization
becomes minimal. It may be acceptable to randomize individual subjects within clusters
given sufficient follow-up time.
The simulation results show that our estimation method produces reasonable estimates with
generally good coverage when the underlying assumptions are correct. The over-coverage of
the compliance superclass probability estimates seems to indicate that our estimates may be
too conservative.
In our analysis we assume three compliance superclasses, the maximum number of latent
classes that can be identified when the dichotomous “outcomes” (in this case the compliance
class membership) are available (Goodman 1974). However, our model fit analysis using
PPD-probabilities showed that while model fit for the 3-superclass model (p=0.046) was
better than for the 2-superclass model (p=0.003), it was still less than ideal. Hence we are
currently exploring Markov Chain models for the compliance classes as a richer model than
the “conditional independence” model considered here.
Beyond relaxing the conditional independence assumption of compliance classes across time
given superclass and covariates, we can also consider incorporating other covariates in modelling the compliance classes and superclasses to identify better predictors of compliance. If
clinicians can identify patients who are likely to comply to treatment over time and those less
likely to comply, then they may be able to target patients with particular attributes or tailor
treatment for different patients to optimize treatment adherence and treatment outcomes.
The reviewers raised an important issue of the effect of prior outcomes on compliance behaviors. In this analysis we model the joint distribution of the compliance classes and the
outcomes as a product of the joint distribution of compliance classes and joint distribution
of the outcomes conditional on the joint distribution of the compliance classes:
f (Yi1 , · · · , YiJi , Ci1 , · · · , CiJi ) = f (Yi1 , · · · , YiJi |Ci1 , · · · , CiJi )f (Ci1 , · · · , CiJi )
This allows us to incorporate the relationship between compliance classes and prior outcomes,
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though this relationship is not modelled explicitly. Alternatively we can model the joint
distributions as a time series:

f (Yi1 , · · · , YiJi , Ci1 , · · · , CJi )
= P (Ci1 )P (Yi1 |Ci1 )P (Ci2 |Yi1 , Ci1 )P (Yi2 |Ci1 , Ci2 , Yi1 ) · · ·
P (CiJi |Yi1 , · · · , Yi,Ji −1 , Ci1 , · · · , Ci,Ji −1 )P (YiJi |Ci1 , · · · , CiJi , Yi1 , · · · , Yi,Ji −1 )
However, examining this model raised the issue of identifiability in a potential outcomes
framework, and it is not clear how one would construct meaningful ITT contrasts in this
setting. Nonetheless, it would be valuable to explore the relationship between prior outcomes
and compliance behaviors in future work.

24

http://biostats.bepress.com/upennbiostat/art10

5
5.1

Appendix
Proof within-superclass ITT effects are the same under the
transient, non-transient, and decay models assuming compliance classes at each time points are conditionally independent
from each other given compliance superclass.

We consider transient, non-transient, and decay models. We are interested in the ITT
contrast within superclass.
E[Yij (Z = 1)|Ui = k] − E[Yij (Z = 0)|Ui = k]
Let λ∗jηz be the compliance class-specific effect of randomization on the outcome for compliance class η at time j when randomized to treatment group z under the transient model, and
λjηz be the compliance class-specific effect of randomization under the non-transient model.
ITT contrast at time j under transient model:
P (Cij = c|Ui = k)(λ∗jc1 − λ∗jc0 ) + P (Cij = n|Ui = k)(λ∗jn1 − λ∗jn0 )
ITT contrast at time j under non-transient model:
P (Ci1 = c|Ui = k)(λ1c1 − λ1c0 ) + P (Ci1 = n|Ui = k)(λ1n1 − λ1n0 ) + ...
+P (Cij = c|Ui = k)(λjc1 − λjc0 ) + P (Cij = n|Ui = k)(λjn1 − λjn0 )
= [P (Ci1 = c|Ui = k)λ1c1 + P (Ci1 = n|Ui = k)λ1n1 + ... +
P (Cij = c|Ui = k)λjc1 + P (Cij = n|Ui = k)λjn1 ]

(6)

− [P (Ci1 = c|Ui = k)λ1c0 + P (Ci1 = n|Ui = k)λ1n0 + ... +
P (Cij = c|Ui = k)λjc0 + P (Cij = n|Ui = k)λjn0 ]
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P (Ci,j−1 = c|Ui = k)λj−1,cz + P (Ci,j−1 = n|Ui = k)λj−1,nz
= [P (Ci,j−1 = c, Cij = c|Ui = k) + P (Ci,j−1 = c, Cij = n|Ui = k)] λj−1,cz
+ [P (Ci,j−1 = n, Cij = c|Ui = k) + P (Ci,j−1 = n, Cij = n|Ui = k)] λj−1,nz
= [P (Ci,j−1 = c|Ui = k)P (Cij = c|Ui = k) + P (Ci,j−1 = c|Ui = k)P (Cij = n|Ui = k)] λj−1,cz
+ [P (Ci,j−1 = n|Ui = k)P (Cij = c|Ui = k) + P (Ci,j−1 = n|Ui = k)P (Cij = n|Ui = k)] λj−1,nz
assuming conditional independence of compliance probabilities given superclass.

P (Ci1 = c|Ui = k)λ1c1 + P (Ci1 = n|Ui = k)λ1n1
= [P (Ci1 = c, Ci2 = c, ..., Cij = c|Ui = k) + ... + P (Ci1 = c, Ci2 = n, ..., Cij = n|Ui = k)] λ1c1
+ [P (Ci1 = n, Ci2 = c, ..., Cij = c|Ui = k) + ... + P (Ci1 = n, Ci2 = n, ..., Cij = n|Ui = k)] λ1n1
summing over all 2j−1 compliance patterns for Ci2 to Cij .
= [P (Ci1 = c, Ci2 = c, ..., Ci,j−1 = c|Ui = k)P (Cij = c|Ui = k) + ...+
P (Ci1 = c, Ci2 = n, ..., Ci,j−1 = n|Ui = k)P (Cij = n|Ui = k)] λ1c1
+ [P (Ci1 = n, Ci2 = c, ..., Ci,j−1 = c|Ui = k)P (Cij = c|Ui = k) + ...+
P (Ci1 = n, Ci2 = n, ..., Ci,j−1 = n|Ui = k)P (Cij = n|Ui = k)] λ1n1
= [P (Ci1 = c|Ui = k)P (Cij = c|Ui = k) + P (Ci1 = c|Ui = k)P (Cij = n|Ui = k)] λ1c1
+ [P (Ci1 = n|Ui = k)P (Cij = c|Ui = k) + P (Ci1 = n|Ui = k)P (Cij = n|Ui = k)] λ1n1

P (Ci1 = c|Ui = k)λ1c0 + P (Ci1 = n|Ui = k)λ1n0
= [P (Ci1 = c, Ci2 = c, ..., Cij = c|Ui = k) + ... + P (Ci1 = c, Ci2 = n, ..., Cij = n|Ui = k)] λ1c0
+ [P (Ci1 = n, Ci2 = c, ..., Cij = c|Ui = k) + ... + P (Ci1 = n, Ci2 = n, ..., Cij = n|Ui = k)] λ1n0
= [P (Ci1 = c, Ci2 = c, ..., Ci,j−1 = c|Ui = k)P (Cij = c|Ui = k) + ...+
P (Ci1 = c, Ci2 = n, ..., Ci,j−1 = n|Ui = k)P (Cij = n|Ui = k)] λ1c0
+ [P (Ci1 = n, Ci2 = c, ..., Ci,j−1 = c|Ui = k)P (Cij = c|Ui = k) + ...+
P (Ci1 = n, Ci2 = n, ..., Ci,j−1 = n|Ui = k)P (Cij = n|Ui = k)] λ1n0
= [P (Ci1 = c|Ui = k)P (Cij = c|Ui = k) + P (Ci1 = c|Ui = k)P (Cij = n|Ui = k)] λ1c0
+ [P (Ci1 = n|Ui = k)P (Cij = c|Ui = k) + P (Ci1 = n|Ui = k)P (Cij = n|Ui = k)] λ1n0
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Then equation (6) becomes:
P (Cij = c|Ui = k) [P (Ci1 = c|Ui = k)λ1c1 + P (Ci1 = n|Ui = k)λ1n1 +
P (Ci2 = c|Ui = k)λ2c1 + P (Ci2 = n|Ui = k)λ2n1 + ...+
P (Ci,j−1 = c|Ui = k)λj−1,c,1 + P (Ci,j−1 = n|Ui = k)λj−1,n,1 + λjc1 ]
+P (Cij = n|Ui = k) [P (Ci1 = c|Ui = k)λ1c1 + P (Ci1 = n|Ui = k)λ1n1 +
P (Ci2 = c|Ui = k)λ2c1 + P (Ci2 = n|Ui = k)λ2n1 + ...+
P (Ci,j−1 = c|Ui = k)λj−1,c,1 + P (Ci,j−1 = n|Ui = k)λj−1,n,1 + λjn1 ]
−P (Cij = c|Ui = k) [P (Ci1 = c|Ui = k)λ1c0 + P (Ci1 = n|Ui = k)λ1n0 +
P (Ci2 = c|Ui = k)λ2c0 + P (Ci2 = n|Ui = k)λ2n0 + ...+
P (Ci,j−1 = c|Ui = k)λj−1,c,0 + P (Ci,j−1 = n|Ui = k)λj−1,n,0 + λjc0 ]
−P (Cij = n|Ui = k) [P (Ci1 = c|Ui = k)λ1c0 + P (Ci1 = n|Ui = k)λ1n0 +
P (Ci2 = c|Ui = k)λ2c0 + P (Ci2 = n|Ui = k)λ2n0 + ...+
P (Ci,j−1 = c|Ui = k)λj−1,c,0 + P (Ci,j−1 = n|Ui = k)λj−1,n,0 + λjn0 ]
= P (Cij = c|Ui = k)λ∗jc1 + P (Cij = n|Ui = k)λ∗jn1
−P (Cij = c|Ui = k)λ∗jc0 − P (Cij = n|Ui = k)λ∗jn0
= P (Cij = c|Ui = k)(λ∗jc1 − λ∗jc0 ) + P (Cij = n|Ui = k)(λ∗jn1 − λ∗jn0 )

Therefore, when fitting transient model to non-transient data, we still get unbiased ITT
effect within superclass. A similar proof shows that fitting transient model to data from
decay model would still give us unbiased ITT effect within superlcass.
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5.2

Conditional draws of the Gibbs sampler

Let Yi , denote the column vector of Yij for subject i. For simplicity, Let
Xij = [I(Ci1 = c, Zi = 0), · · · , I(Ci5 = n, Zi = 1), Ai ] denote the row vector of the fixed
effect, and Xi denote the design matrix of the fixed effect for subject i with Ji rows. Let
β = [λ1c0 , · · · , λ5n1 , γ] denote the vector of coefficients corresponding to fixed effect.
The distributions from which parameters are drawn at each iteration in the Gibbs sampling
are as follows:
¡
¢
β|X, Y, W, ϕ, σ 2 , µβ , Σ−1
∼ M V N (µ̂, Σ̂)
β
P
−1
T
T
σ −2 N
i=1 Xi (Yi −Wi ϕi )+Σβ µβ
PN
µ̂ =
−1
T
−2
σ
i=1 Xi Xi +Σβ
P
N
−1
Σ̂ = (σ −2 i=1 XTi Xi + Σ−1
β )

´
³
PN
P
i=1 Fi +νσ ψ
P
(σ 2 |X, Y, W, ϕ, β, νσ , ψ) ∼ Inv − χ2 df = N
J
+
ν
,
σ
N
i=1 i
i=1 Ji +νσ
¡
¢
¡
¢
T
where Fi = Yi − Xi β − WiT ϕi
Yi − Xi β − WiT ϕi

³
´
(ϕi |Xi , Yi , Wi , β, σ 2 , Σϕ , ) ∼ M V N ϕ̂i V̂i , V̂i
WT (Yi −Xi β )
ϕ̂i = i σ2
³ T
´−1
Wi Wi
−1
+
V̂i =
Σ
ϕ
σ2

³
(Σϕ |ϕ, νϕ , Γ) ∼ Inv − W ishart df = νϕ + N,

PN

T
i=1 ϕi ϕi

´
+Γ

In studies where the control group have no access to the intervention, such as the PROSPECT
study, the only possible compliance classes are compliers and never-takers. Therefore πkjc (Qi ) =
exp(α0kjc + α1c Qi )/[1 + exp(α0kjc + α1c Qi )] and πkjn (Qi ) = 1/[1 + exp(α0kjc + α1c Qi )]. The
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posterior probabilities of compliance class membership is:
P (Cij = c|Yij , Zi , Dij , Ui , λ, Ai , γ, Wi , ϕi , Qi , α, σ 2 )



T
Yij −(λjc0 +AT
i γ +Wi ϕi )

π
(Q
)×φ
i
kjc
σ


!# if ∈ Zi = 0, Dij = 0, Ui = k

 P "
Yij −(λjη 0 0 +AT γ +WT ϕi )
i
i
η 0 πkjη 0 (Qi )×φ
σ
=



0
if ∈ Zi = 1, Dij = 0, Ui = k


1
if ∈ Zi = 1, Dij = 1, Ui = k

P (Cij = n|Yij , Zi , Dij , Ui , λ, Ai , γ, Wi , ϕi , Qi , α, σ 2 )



T
Y −(λjn0 +AT
i γ +Wi ϕi )

πkjn (Qi )×φ ij
σ


!# if ∈ Zi = 0, Dij = 0, Ui = k

 P "
Yij −(λjη 0 0 +AT γ +WT ϕi )
i
i
π
(Q
)×φ
0
i
kjη
η0
σ
=



1
if ∈ Zi = 1, Dij = 0, Ui = k


0
if ∈ Zi = 1, Dij = 1, Ui = k

The posterior probabilities of compliance superclass is:
(p1 , ..., pK |U, a1 , ..., aK ) ∼ Dirichlet(r1 , ..., rK )
P
r1 = N
1 I(Ui = 1) + a1
P
rK = N
1 I(Ui = K) + aK

Let Ci denote the vector of Cij for subject i, and α denote the vector of α0kjη and α1η . The
posterior probability of compliance superclass membership is:

P (Ui = k|Ci , Qi , α, p1 , ..., pK ) ∝ pk ×

Ji Y
Y

0

πkjη0 (Qi )I(Cij =η ,Ui =k)

j=1 η 0

Estimation of the parameters is a MCMC process. Note that λjηz is a function of the compliance class, Cij ; and α0kjη is a function of the compliance superclass, Ui . The parameters
λjηz , α0kjη , and α1η are updated at each iteration with the latest estimates of Cij and Ui ,
which are then used to estimate Cij and Ui in the next iteration.
29

Hosted by The Berkeley Electronic Press

6

REFERENCES
Angrist, J. D., Imbens, G. W., and Rubin, D. B. (1996), “Identification of Causal Effects
Using Instrumental Variables,” Journal of the American Statistical Association, 91,
444-455.
Baker, S. G., and Lindeman, K. S. (1994), “The Paired Availability Design: A Proposal
For Evaluating Epidural Analgesia During Labor,” Statistics in Medicine, 13, 22692278.
Bruce, M. L., Ten Have, T. R., Reynolds, C. F., Katz, I. R., Schulberg, H. C., Mulstant,
B. H., Brown, G. K., McAvay, G. J., Pearson, J. L., and Alexopoulos, G. S. (2004),
“Reducing Suicidal Ideation and Depressive Symptoms in Depressed Older Primary
Care Patients,” Journal of the American Medical Association, 291, 1081-1091.
Clogg, C. C. (1995), “Latent Class Models,” in Handbook of Statistical Modeling for the
Social and Behavioral Sciences, eds. G. Arminger, C. C. Clogg, and M. E. Sobel,
New York: Plenum Press.
Elliott, M. R., Gallo, J. J., Ten Have, T. R., Bogner, H. R., and Katz, I. R. (2005), “Using
a Bayesian Latent Growth Curve Model to Identify Trajectories of Positive Affect and
Negative Events Following Myocardial Infarction,” Biostatistics, 6, 119-143.
Frangakis, C. E., Brookmeyer, R. S., Varadhan, R., Safaeian, M., Vlahov, D., and
Strathdee, S. A. (2004), “Methodology for Evaluating a Partially Controlled Longitudinal Treatment Using Principal Stratification, With Application to a Needle
Exchange Program,” Journal of the American Statistical Association, 99, 239-249.
Frangakis, C. E., and Rubin, D. B. (1999), “Addressing Complications of Intention-ToTreat Analysis In the Combined Presence of All-Or-None Treatment-Noncompliance
and Subsequent Missing Outcomes,” Biometrika, 86, 365-379.
— (2002), “Principal Stratification in Causal Inference,” Biometrics, 58, 21-29.

30

http://biostats.bepress.com/upennbiostat/art10

Garrett, E. S., and Zeger, S. L. (2000), “Latent Class Model Diagnosis,” Biometrics, 56,
1055-1067.
Gelfand, A. E., and Smith, A. F. M. (1990), “Sampling-Based Approaches to Calculating
Marginal Densities,” Journal of the American Statistical Association, 85, 398-409.
Gelman, A., Carlin, J. B., Stern, H. S., and Rubin, D. B. (2004), Bayesian Data Analysis
(2nd ed.), New York: Chapman and Hall.
Geman, S., and Geman, D. (1984). “Stochastic Relaxation, Gibbs Distributions, and
the Bayesian Restoration of Images,” IEEE Transactions on Pattern Analysis and
Machine Intelligence, 6, 721-741.
Goodman, L. A. (1974). “Exploratory Latent Structure Analysis Using Both Identifiable
and Unidentifiable Models,” Biometrika 61, 215-231.
Hastings, W. K. (1970), “Monte Carlo Sampling Methods Using Markov Chains and
Their Applications,” Biometrika, 57, 97-109.
Heitjan, D. F. (1999), “Ignorability and Bias In Clinical Trials,” Statistics in Medicine,
18, 2421-2434.
Hirano K., Imbens, G. W., Rubin, D. B., and Zhou, X. (2000), “Assessing the Effect of
an Influenza Vaccine in an Encouragement Design,” Biostatistics, 1, 69-88.
Hogan, J. W., and Daniels, M. J. (2002), “A Hierarchical Modelling Approach to Analysing
Longitudinal Data With Drop-out and Non-compliance, With Application to an
Equivalence Trial in Paediatric Acquired Immune Deficiency Syndrome,” Applied Statistics, 51, Part 1, 1-21.
Imbens, G. W. and Rubin, D. B. (1997), “Bayesian Inference for Causal Effects in Randomized Experiments With Noncompliance,” The Annals of Statistics, 25, 305-327.
Jo, B., and Muthén, B. (2001), “Longitudinal Studies With Intervention and Noncompliance: Estimation of Causal Effects in Growth Curve Mixture Modeling,” in Multilevel
31

Hosted by The Berkeley Electronic Press

Modeling: Methodological Advances, Issues, and Applications, eds. N. Duan and S.
P. Reise, New York: Lawrence Erlbaum Associates, pp. 51-62.
Little, R. J. and Rubin, D. B. (2000), “Causal Effects in Clinical and Epidemiological Studies via Potential Outcomes: Concept and Analytical Approaches,” Annual
Reviews of Public Health, 21, 121-145.
— (2002), Statistical Analysis With Missing Data (2nd ed.), New York: John Wiley and
Sons Inc.
Little, R. J., and Yau, L. H. Y. (1998), “Statistical Techniques for Analyzing Data From
Prevention Trials: Treatment of No-Shows Using Rubin’s Causal Model,” Psychological Methods, 3, 2, 147-159.
Mealli, F., Imbens, G. W., Ferro, S., and Biggeri, A. (2004), “Analyzing A Randomized
Trial On Breast Self-Examination With Noncompliance and Missing Outcomes,” Biostatistics, 5, 207-222.
Peng, Y., Little, R. J. A., and Raghunathan, T. E. (2004), “An Extended General Location Model for Causal Inference from Data Subject to Noncompliance and Missing
Values,” Biometrics, 60, 598-607.
Rubin, D. B. (1978), “Bayesian Inference For Causal Effects: The Role of Randomization,” The Annals of Statistics, 6, 34-58.
— (1986), “Statistics and Causal Inference. Comment: Which Ifs Have Causal Answers,”
Journal of the American Statistical Association, 81, 961-962.
Stephens, M. (2000), “Dealing With Label Switching In Mixture Models,” Journal of the
Royal Statistical Society, Series B, 62, 795-809.
Ten Have, T. R., Elliott, M. R., Joffe, M., Zanutto, E., and Datto, C. (2004), “Causal
Models for Randomized Physician Encouragement Trials in Treating in Primary Care
Depression,” Journal of the American Statistical Association, 99, 16-25.

32

http://biostats.bepress.com/upennbiostat/art10

Yau, L. H. Y., little, R. J. (2001), “Inference for the Complier-Average Causal Effect From
Longitudinal Data Subject to Noncompliance and Missing Data, With Application to
a Job Training Assessment for the Unemployed,” Journal of the American Statistical
Association, 96, 1232-1244.

33

Hosted by The Berkeley Electronic Press

7

TABLES

Table 1. ITT and AT Estimates of Treatment Effect and Corresponding 95% Confidence
Intervals (in parentheses).
Time
4-months
8-months
12-months
18-months
24-months

ITT Effects
-2.97 (-4.20,-1.74)
-1.58 (-2.84,-0.32)
-1.32 (-2.63,-0.01)
-0.66 (-1.98, 0.66)
-1.42 (-2.83,-0.01)

AT Effects
-2.54 (-3.67,-1.41)
-1.22 (-2.39,-0.04)
-1.31 (-2.53,-0.09)
-1.31 (-2.55,-0.07)
-2.10 (-3.44,-0.77)

Table 2. Posterior Means and 95% Credible Intervals (in parentheses) for the Time- and
Compliance Superclass-Varying Compliance Probabilities Given Average HAMD 18.1 and
Compliance Superclass Probabilities.
Time
4-months
8-months
12-months
18-months
24-months
P (Ui = k)

Low
Compliers
0.37(0.13,0.57)
0.14(0.02,0.35)
0.08(0.02,0.21)
0.13(0.04,0.28)
0.14(0.03,0.34)
0.19(0.12,0.26)

Decreasing
High
Compliers
Compliers
0.85(0.26,0.99) 0.99(0.97,1.00)
0.80(0.23,0.99) 0.99(0.97,1.00)
0.51(0.13,0.96) 0.99(0.96,1.00)
0.33(0.03,0.94) 0.98(0084,1.00)
0.22(0.02,0.92) 0.89(0.82,0.95)
0.07(0.00,0.14) 0.74(0.67,0.80)

Table 3. Posterior Means and 95% Credible Intervals (in parentheses) for the ITT Effect of
Intervention Within Compliance Superclasses.
Low
Time
Compliers
4-months -9.00(-12.58,-6.14)
8-months -4.47(- 8.66, 0.17)
12-months 1.69(- 4.47, 5.56)
18-months 1.71(- 1.75, 5.01)
24-months -0.47(- 3.54, 2.54)

Decreasing
High
Compliers
Compliers
-3.19(-10.45,-0.70) -1.53(-2.87,-0.16)
-1.76(- 2.86, 0.16) -0.88(-2.41, 0.71)
0.05(- 2.89, 3.23) -1.84(-3.42,-0.11)
1.13(- 2.50, 4.69) -1.23(-2.84, 0.38)
-0.44(- 3.30, 2.89) -1.62(-3.32,-0.02)
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Table 4. Mean Estimated Compliance Probabilities, Compliance Superclass Probabilities,
and ITT Effect of Intervention Within Compliance Superclasses (true value in parentheses)
From 100 Simulations.
Visit
1
2
3
4
5
P (Ui = k)

Increasing-Noncompliers
P (Cij = c)
Effect
0.51(0.5) -2.99(-2.95)
0.40(0.4) -1.60(-1.73)
0.30(0.3) -0.80(-1.24)
0.20(0.2)
0.91( 0.46)
0.11(0.1)
0.21(-0.13)
0.50(0.50)

Steady-Compliers
P (Cij = c)
Effect
0.89(0.9) -2.83(-3.03)
0.90(0.9) -1.37(-1.56)
0.89(0.9) -1.27(-1.01)
0.89(0.9) -0.89(-0.64)
0.88(0.9) -1.79(-1.56)
0.50(0.50)

Table 5. Coverage of 95% Credible Intervals for Estimated Compliance Probabilities, Compliance Superclass Probabilities, and ITT Effect of Intervention Within Compliance Superclasses From 100 Simulations.
IncreasingNoncompliers
Visit
P (Cij = c) Effect
1
92%
98%
2
97%
99%
3
98%
98%
4
93%
100%
5
97%
99%
P (Ui = k)
100%

SteadyCompliers
P (Cij = c) Effect
95%
98%
96%
99%
94%
98%
95%
99%
92%
99%
100%
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